Antiviral activity of 1-(1-arylimidazolidine-2-ylidene)-3-(4-chlorobenzyl)urea derivatives
More details
Hide details
Department of Virology, Medical University, Lublin, Poland
Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modelling Unit, Medical University, Lublin, Poland
Barbara Rajtar   

Department of Virology, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland
J Pre Clin Clin Res. 2013;7(2):104–106
The aim of the study was evaluation of the biological activity of 1-(1-arylimidazolidine-2-ylidene)-3-(4-chlorobenzyl)urea derivatives (I – IV) against the Coxsackievirus B3 (CVB3). The cytotoxic activity was tested in HEK293 cell culture. Cells were incubated for 72 hours at 37° C in a 5% CO2 atmosphere. Cytotoxicity of substances was measured by the MTT test. After determining the highest non-toxic concentration of substances their activity against the Coxsackievirus B3 from the Picornaviridae family was estimated. In order to check the antiviral activity of the compounds, a virus suspension was added to the cell culture and incubated for 1 hour at 37 °C. The virus was then removed from the culture and the tested compounds were added. The cell culture was incubated at 37° C in a 5% CO2 atmosphere until the cytophatic effect in the virus control was achieved, and then the virus was titrated. The virus titre was calculated by the Reed-Muench method. EC50 values of compounds I – IV were contained within the range of 211.4 – 359.7 μg/ml. The research demonstrated that only compound II slightly influenced the CVB3 replication by reducing the virus replication level by 0.77 log, which resulted in reducing the titre by 12.8%.
Krawczyk E, Łuczak M. Antiviral activity of natural compounds and their derivatives. (article in Polish). Post Mikrobiol. 2005; 44(3): 239–252.
Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005; 111(7): 887–893.
Wang YF, Wang XY, Ren Z, Qian CW, Li YC, Kaio K et al. Phyllaemblicin B inhibits Coxsackievirus B3 induced apoptosis and myocarditis. Antiviral Res. 2009; 84(2): 150–158.
Knowlton KU. CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol. 2008; 323: 315–335.
Takenouchi T, Munekata E. Amyloid beta-peptide-induced inhibition of MTT reduction in PC12h and C1300 neuroblastoma cells: effect of nitroprusside. Peptides 1998; 19(2): 365–372.
Reed LJ, Muench MA. A simple method of estimating fifty percent end points. Am J Hyg 1938; 27: 493–497.
Kwak SH, Bang SC, Seo HH, Shin HR, Lee KC, Le Hoang TA, Jung SH. Evaluation of anticancer activity of 4-vinyl arylsulfonylimidazolidinones. Arch Pharm Res. 2006; 29(9): 721–727.
Gubnitskaya ES, Loseva IM, Stukalo EA. Synthesis and antitumor activity of N-[2-(diethylenediamidophosphonyl)vinyl]-N’-arylureas. Pharmaceutical Chemistry Journal 1974; 8(9): 531–533.
Agadzhanyan TsE, Arutyunyan AD, Stepanyan NO, Bunatyan ZhM. Synthesis and hypoglycemic activity of N-arylsulfonyl-N’-[7-(1,3,5-triazaadamantyl)]urea. Pharmaceutical Chemistry Journal. 1997; 31(1):15–16.
Rządkowska M, Szacoń E, Matosiuk D, Kędzierska E, Fidecka S. Synthesis of new 1-aryl-6-benzylimidazo[1,2-a][1,3,5]triazines with potential pharmacological activity. Acta Pol Pharm. 2012; 69(6): 1270–1275.
Aguado L, Canela MD, Thibaut HJ, Priego EM, Camarasa MJ, Leyssen P, Neyts J, Perez-Perez MJ. Efficient synthesis and anti-enteroviral activity of 9-arylpurines. Eur J Med Chem. 2012; 49: 279–288.
Aguado L, Thibaut HJ, Priego EM, Jimeno ML, Camarasa MJ, Neyts J, Perez-Perez MJ. 9-Arylpurines as a novel class of enterovirus inhibitors. J Med Chem. 2010; 53(1): 316–324.
Xu X, Xie H, Wang Y, Wei X. A-type proanthocyanidins from lychee seeds and their antioxidant and antiviral activities. J Agric Food Chem. 2010; 58(22): 11667–11672.